Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BOLT Bolt Biotherapeutics Inc
- Stocks
- Healthcare
- NASDAQ: BOLT
Price (delayed)
$5.75
Market cap
$11.02M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$33.2
Enterprise value
$26.56M
Bolt Biotherapeutics, Inc. is a clinical-stage immuno-oncology company developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. Bolt’s proprietary Boltbody™ Immune-stimulating Antibody Conjugate (ISAC) approach
Highlights
Bolt Biotherapeutics's gross profit has plunged by 68% YoY and by 53% from the previous quarter
The revenue has shrunk by 68% YoY and by 53% QoQ
Key stats
What are the main financial stats of BOLT
Market
Valuations
Earnings
Shares outstanding
1.92M
Market cap
$11.02M
Enterprise value
$26.56M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.24
Price to sales (P/S)
3.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.3
Revenue
$3.64M
Gross profit
$3.64M
Operating income
-$68.07M
Net income
-$63.35M
EBIT
-$63.35M
EBITDA
-$59.49M
Free cash flow
-$56.83M
Per share
Balance sheet
Liquidity
EPS
-$33.2
EPS diluted
-$33.2
Free cash flow per share
-$29.65
Book value per share
$24.42
Revenue per share
$1.9
TBVPS
$44.79
Total assets
$85.86M
Total liabilities
$39.05M
Debt
$24.71M
Equity
$46.81M
Working capital
$28.95M
Debt to equity
0.53
Current ratio
3.13
Quick ratio
2.92
Net debt/EBITDA
-0.26
Margins
Efficiency
Dividend
EBITDA margin
-1,635.1%
Gross margin
100%
Net margin
-1,741.3%
Operating margin
-1,871.1%
Return on assets
-60.5%
Return on equity
-96.8%
Return on invested capital
-62.5%
Return on capital employed
-87.6%
Return on sales
-1,741.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BOLT stock price
How has the Bolt Biotherapeutics stock price performed over time
Intraday
2.5%
1 week
1.59%
1 month
-10.71%
1 year
-60.62%
YTD
-46.26%
QTD
-28.13%
Financial performance
How have Bolt Biotherapeutics's revenue and profit performed over time
Revenue
$3.64M
Gross profit
$3.64M
Operating income
-$68.07M
Net income
-$63.35M
Gross margin
100%
Net margin
-1,741.3%
Bolt Biotherapeutics's operating margin has plunged by 183% YoY and by 97% from the previous quarter
The net margin has plunged by 112% from the previous quarter
Bolt Biotherapeutics's gross profit has plunged by 68% YoY and by 53% from the previous quarter
The revenue has shrunk by 68% YoY and by 53% QoQ
Price vs fundamentals
How does BOLT's price correlate with its fundamentals
Growth
What is Bolt Biotherapeutics's growth rate over time
Valuation
What is Bolt Biotherapeutics stock price valuation
P/E
N/A
P/B
0.24
P/S
3.03
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.3
BOLT's P/B is 70% below its 5-year quarterly average of 0.8 and 20% below its last 4 quarters average of 0.3
The equity has plunged by 55% YoY and by 18% from the previous quarter
The stock's P/S is 100% less than its 5-year quarterly average of 715.5
The revenue has shrunk by 68% YoY and by 53% QoQ
Efficiency
How efficient is Bolt Biotherapeutics business performance
The ROS has plunged by 112% from the previous quarter
The ROE has shrunk by 87% YoY and by 22% QoQ
Bolt Biotherapeutics's ROA has plunged by 60% YoY and by 14% from the previous quarter
Bolt Biotherapeutics's ROIC has plunged by 57% YoY and by 13% from the previous quarter
Dividends
What is BOLT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BOLT.
Financial health
How did Bolt Biotherapeutics financials performed over time
The total assets is 120% greater than the total liabilities
The quick ratio has contracted by 48% YoY and by 3.6% from the previous quarter
The company's current ratio fell by 45% YoY and by 2.2% QoQ
The debt is 47% less than the equity
BOLT's debt to equity has soared by 179% YoY and by 20% from the previous quarter
The equity has plunged by 55% YoY and by 18% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.